Rosuvastatin calcium and process for producing intermediate thereof
US-2024360086-A1 · Oct 31, 2024 · US
US10407702B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10407702-B2 |
| Application number | US-201715665572-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 1, 2017 |
| Priority date | Dec 7, 2012 |
| Publication date | Sep 10, 2019 |
| Grant date | Sep 10, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A novel process is provided for the efficient preparation of an asymmetric compound of structural formula I: employing dynamic kinetic resolution (DKR). The DKR process involves an enzymatic enantioselective amination reaction catalyzed by transaminases. The process can be used to manufacture key intermediates in the preparation of poly (ADP-ribose) polymerase (PARP) inhibitors which may be useful for the treatment of cancer.
Opening claim text (preview).
What is claimed is: 1. A process for preparing an asymmetric compound of Formula I: wherein: R 1 is a leaving group, a protected amino group, NO 2 , or OH or its protected form; R 2 is hydrogen; R 3 is (C═O)OR 5 , CH 2 R 6 , or a protected aldehyde; or, R 2 and R 3 are combined to form a nitrogen containing heterocyclyl selected from R 4 is hydrogen or an amino protecting group; R 5 is C 1-6 alkyl, C 3-10 cycloalkyl, C 4-10 heterocyclyl, aryl, or heteroaryl; and, R 6 is a leaving group or OH or its protected form; comprising a biocatalytic transamination of a compound of Formula II: wherein: R 1 is as defined above; R 2′ is an aldehyde or an aldehyde equivalent; and, R 3′ is R 3 ; or R 2′ and R 3′ are combined to form in the presence of a transaminase polypeptide, a coenzyme, and an amino donor; wherein the transaminase polypeptide is selected from the group consisting of the amino acid sequence as set forth in SEQ ID NO: 172, 174, 176, 178, 180, 182, 184, 186, 188, and 190. 2. The process of claim 1 , wherein the biocatalytic transamination provides a compound of Formula I having an enantiomeric excess of at least 95%. 3. The process of claim 1 , wherein the transaminase polypeptide is SEQ ID NO: 180. 4. The process of claim 1 , wherein the coenzyme is pyridoxal-phosphate (PLP). 5. The process of claim 1 , wherein the amino donor is isopropylamine. 6. The process of claim 1 , wherein the transaminase polypeptide is SEQ ID NO: 180, the coenzyme is PLP, and the amino donor is isopropylamine. 7. The process of claim 1 , wherein R 1 is Br. 8. The process of claim 1 , wherein R 2 and R 3 are combined to form a nitrogen containing heterocyclyl selected from and R 4 is hydrogen. 9. The process of claim 8 , wherein R 2 and R 3 are combined to form and R 4 is hydrogen. 10. The process of claim 1 , wherein R 1 is Br, R 2 and R 3 are combined to form and R 4 is hydrogen. 11. The process of claim 8 , wherein R 2 is hydrogen, R 3 is CH 2 R 5 , R 4 is hydrogen, and R 5 is OH.
containing a six-membered hetero ring · CPC title
transferring nitrogenous groups (2.6) · CPC title
Transaminases (2.6.1) · CPC title
Preparation by ring-closure or hydrogenation · CPC title
Amines; Imines · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.